Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from EQL Pharma AB ( (SE:EQL) ) is now available.
EQL Pharma AB’s key product, methenamine hippurate, branded as Altaromin©, has received marketing approval in France. This approval allows French patients with recurring urinary tract infections access to a non-antibiotic alternative, potentially reducing the risk of antibiotic-resistant bacteria. The product will be launched in early 2026, subject to reimbursement approvals, and will be marketed by EQL’s partner, Laboratoires Majorelle.
More about EQL Pharma AB
EQL Pharma AB specializes in developing and selling generic drugs that are medically equivalent to original drugs. The company has launched 46 niche generics in the Nordic markets and focuses on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB is based in Lund, Sweden, and is listed on the Nasdaq Stockholm stock market.
Average Trading Volume: 16,759
Current Market Cap: SEK2.67B
Find detailed analytics on EQL stock on TipRanks’ Stock Analysis page.